SAN DIEGO, Oct. 29, 2018 /PRNewswire/ -- Aethlon Medical, Inc.
(Nasdaq:AEMD), an immunotherapeutic technology company focused on unmet needs in global health, today announced that its CEO,
Jim Joyce, will present at the NYC Oncology Investor Conference on Tuesday,
October 30, 2018 at 10:50 a.m. Eastern Time. The event is being held at Rockefeller
Center, 1270 6th Avenue, New York, New York.
About Aethlon Medical, Inc.
Aethlon Medical is focused on addressing unmet needs in global health. The Aethlon Hemopurifier® is a clinical-stage
immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier® depletes
the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis and inhibit the
benefit of leading cancer therapies. The Hemopurifier® is also an FDA designated "Breakthrough Device" related to the treatment
of life-threatening viruses that are not addressed with approved therapies. Additionally, Aethlon owns 80% of Exosome Sciences,
Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease
progression. Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com. You can also connect with us on Twitter, LinkedIn and Facebook.
ABOUT THE NYC ONCOLOGY INVESTOR CONFERENCE
The NYC Oncology Investor Conference 2018 hosted by OneMed Forum, and sponsored by the National Foundation for Cancer
Research, the International Cancer Impact Fund, Klosters Innovation Partners, Venable Law Firm, Torreya Partners, and Marcum is
the leading conference for early-stage private and public cancer investing. For more information about the conference,
please visit www.nyconcologyconference.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as
"may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions
constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and
actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute
to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or
any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, that
the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the
Company's products, the Company's ability to raise capital when needed, the Company's ability to complete the development of its
planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of
government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of
market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is
illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in
forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year
ended March 31, 2018, and in the Company's other filings with the Securities and Exchange
Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this
information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 extension 3300
Jfrakes@aethlonmedical.com
View original content:http://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-the-nyc-oncology-conference-300738772.html
SOURCE Aethlon Medical, Inc.